21 search results for “actinomycetes” in the Public website
-
Anticancer compounds from actinomycetes
How can we find novel natural products from Actinomycetes that act as growth modulators on mammalian cells? Can we harvest and develop the potential of these novel compounds for industrial and medical biotechnology?
-
Growth and development of actinomycetes
We aim to provide new insights relating to the spectacular multi-cellular life cycle of streptomycetes and other actinobacteria.
-
Environmental and metabolomic study of antibiotic production by actinomycetes
Promotor: Prof.dr. G.P. van Wezel
-
Discovery of novel Antibiotics from Actinomycetes by Integrated Metabolomics & Genomics Approaches
Promotor: G.P. van Wezel, Co-promotor: Y.H. Choi
-
exploitation of a cell wall deficient life style in filamentous actinomycetes
Almost all bacteria are enveloped by a cell wall that provides cellular protection.
-
proteomics-based pipeline for drug and enzyme discovery in filamentous actinomycetes
Can a new proteomics workflow be developed to link genes and gene clusters to bioactive molecules, identify novel compounds and enhance the production in the Streptomyces lividans enzyme?
-
Golsa Nayeb Ghanbar Hosseini
Science
g.nayeb.ghanbar.hosseini@biology.leidenuniv.nl | +31 71 527 2727
-
Structural characterization of the cell envelope of Actinobacteria under changing environments
Bacteria have the ability to alter their morphology in order to adapt to changing environments.
-
Identification and characterization of developmental genes in streptomyces
Promotor: Prof.dr. G.P. van Wezel
-
30 years and Professor: the story of Changsheng Wu
The death of his grandfather in 1988 motivates Changsheng Wu to become a scientist. In 2016, he is awarded the C.J. Kok Jury Award for his thesis on novel antibiotics. Two years later, he will become a Professor at Shangdong University, at the age of 30 years.
-
Horizontal gene transfer and spreading of biosynthetic gene clusters and antimicrobial resistance
Biosynthetic gene clusters (BGCs) for natural products are widespread in microbial genomes, and they are rapidly exchanged. This research assesses the factors that control the spread of BGCs and resistance genes in nature. This includes risk assessment for the spread of engineered DNA in nature.
-
Participants
The CMCB comprises research groups from the Institute of Biology Leiden (IBL), the Leiden Institute of Chemistry (LIC) and the Leiden University Medical Center (LUMC).
-
Controlling growth and morphogenesis of the industrial enzyme producer Streptomyces lividans
Promotor: Prof.dr. G.P. van Wezel, Co-Promotor: E. Vijgenboom
-
Dennis Claessen
Science
d.claessen@biology.leidenuniv.nl | +31 71 527 5052
-
Development & Disease
Development & Disease is one of the four research themes of the Institute of Biology Leiden.
-
Microbial Sciences
In the research programme Microbial Sciences we perform state-of-the-art research in the field of biotechnology and microbial sciences.
-
Regulatory networks in Streptomyces
We aim to unravel the complex and intertwining regulatory systems that control development and antibiotic production in streptomycetes.
-
Chemical Biology
Chemical biology research at the Leiden Institute of Chemistry is aimed at understanding biological processes at the molecular level to strengthen the knowledge base of human health and disease. The approach to achieve this goal is a fundamental chemical one; with the aid of chemical probes biological…
-
Better and faster ways of searching for antibiotics
Antibiotic-resistant bacteria are a major problem worldwide. Molecular biologist Changsheng Wu explored innovative methods of developing new antibiotics more simply and more easily. He also discovered a new type of antibiotic.
- Publication highlights
-
It’s all about the cell wall for brand-new professor Dennis Claessen
Dennis Claessen has been appointed professor of Molecular Microbiology at the Institute of Biology Leiden. With his teaching and research on the cell wall, the professor wants to establish applications in the industry and the medical sector.